[
    {
        "outcome_uid": "d0826449",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "JAK Inhibitor",
        "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 20)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "456cb129"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "HIGH",
                "No of participants": {
                    "JAKi (Tofa)": "239/373 (64.1%)",
                    "MTX monotherapy": "79/186 (42.5%)"
                },
                "Annotation": {
                    "data": "1. JAKi include TOFA.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.51 (1.26 to 1.81)",
                    "Absolute Effect (95% CI)": "217 more per 1,000 (from 110 more to 344 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "3b4a5ff2",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "JAK Inhibitor",
        "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 50)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "456cb129"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "HIGH",
                "No of participants": {
                    "JAKi (Tofa)": "184/373 (49.3%)",
                    "MTX monotherapy": "53/186 (28.5%)"
                },
                "Annotation": {
                    "data": "1. JAKi include TOFA.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.73 (1.35 to 2.22)",
                    "Absolute Effect (95% CI)": "208 more per 1,000 (from 100 more to 348 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "f85da7e6",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "JAK Inhibitor",
        "outcome": "Disease activity (follow up: 2 years; assessed with: ACR 70)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "456cb129"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "HIGH",
                "No of participants": {
                    "JAKi (Tofa)": "128/373 (34.3%)",
                    "MTX monotherapy": "28/186 (15.1%)"
                },
                "Annotation": {
                    "data": "1. JAKi include TOFA.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 2.28 (1.58 to 3.30)",
                    "Absolute Effect (95% CI)": "193 more per 1,000 (from 87 more to 346 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "bf9ea5bc",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "JAK Inhibitor",
        "outcome": "Disease activity (follow up: 2 years; assessed with: DAS28-ESR (Lower values \u2013 > benefit) (MCID -1.17)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "456cb129"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "HIGH",
                "No of participants": {
                    "JAKi (Tofa)": "373",
                    "MTX monotherapy": "186"
                },
                "Annotation": {
                    "data": "1. JAKi include TOFA.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0.6 lower (0.88 lower to 0.32 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "117c0af9",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "JAK Inhibitor",
        "outcome": "Remission (follow up: 2 years; assessed with: DAS28-ESR < 2.6)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "456cb129"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "HIGH",
                "No of participants": {
                    "JAKi (Tofa)": "78/373 (20.9%)",
                    "MTX monotherapy": "18/186 (9.7%)"
                },
                "Annotation": {
                    "data": "1. JAKi include TOFA.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 2.16 (1.34 to 3.50)",
                    "Absolute Effect (95% CI)": "112 more per 1,000 (from 33 more to 242 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "479e960f",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "JAK Inhibitor",
        "outcome": "Radiographic progression (follow up: 2 years; assessed with: mTSS (Lower values \u2013 > benefit) (MCID 4.6)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "456cb129"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "HIGH",
                "No of participants": {
                    "JAKi (Tofa)": "373",
                    "MTX monotherapy": "186"
                },
                "Annotation": {
                    "data": "1. JAKi include TOFA.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 1.53 lower (2.36 lower to 0.7 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "2dfe1252",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "JAK Inhibitor",
        "outcome": "Disability (follow up: 2 years; assessed with: HAQ-DI (Lower values \u2013 > benefit) (MCID -0.22)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "456cb129"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "MODERATE",
                "No of participants": {
                    "JAKi (Tofa)": "373",
                    "MTX monotherapy": "186"
                },
                "Annotation": {
                    "data": "1. JAKi include TOFA.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0.2 lower (0.31 lower to 0.09 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "bbb009a1",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "JAK Inhibitor",
        "outcome": "Serious adverse events (follow up: 2 years)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "456cb129"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "JAKi (Tofa)": "40/373 (10.7%)",
                    "MTX monotherapy": "22/186 (11.8%)"
                },
                "Annotation": {
                    "data": "1. JAKi include TOFA.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.91 (0.56 to 1.48)",
                    "Absolute Effect (95% CI)": "11 fewer per 1,000 (from 52 fewer to 57 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "adf69a1e",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "JAK Inhibitor",
        "outcome": "Withdrawal due to adverse events (follow up: 2 years)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "456cb129"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "JAKi (Tofa)": "40/373 (10.7%)",
                    "MTX monotherapy": "25/186 (13.4%)"
                },
                "Annotation": {
                    "data": "1. JAKi include TOFA.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.80 (0.50 to 1.27)",
                    "Absolute Effect (95% CI)": "27 fewer per 1,000 (from 67 fewer to 36 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "979d5da5",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "JAK Inhibitor",
        "outcome": "Death (follow up: 2 years)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "456cb129"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Very low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "JAKi (Tofa)": "3/373 (0.8%)",
                    "MTX monotherapy": "0/186 (0.0%)"
                },
                "Annotation": {
                    "data": "1. JAKi include TOFA.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 3.50 (0.18 to 67.41)",
                    "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "06f3ff99",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "JAK Inhibitor",
        "outcome": "Malignancy (follow up: 2 years)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "456cb129"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "JAKi (Tofa)": "2/373 (0.5%)",
                    "MTX monotherapy": "1/186 (0.5%)"
                },
                "Annotation": {
                    "data": "1. JAKi include TOFA.\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.00 (0.09 to 10.93)",
                    "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 5 fewer to 53 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "9ae722e3",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs exposed RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "JAK Inhibitor",
        "outcome": "Malignancy (from SRs on harms)",
        "related_paper_list": [
            "1fbf0f4e"
        ],
        "assessment_results": {
            "GRADE": {
                "result_interpretation": "The systematic review RefID=1220, 2017 (RCTs=3) comparing tofacitinib 5mg vs placebo + csDMARD among RA showed that for cancer, the result was Peto OR=2.39 (0.50, 11.50)",
                "Study design": "Systematic Review"
            }
        }
    }
]